Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine + capecitabine versus docetaxel + capecitabine for metastatic breast cancer
ISRCTN66842537Phase 2Terminated
- Sponsor
- United States Department of Health and Human Services
- Start
- Apr 2002
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of vinorelbine, capecitabine, docetaxel and dexamethasone in breast cancer (2 arms), sponsored by United States Department of Health and Human Services. Primary endpoints: Toxicity, Response and 1 more. Started Apr 2002; status: terminated.
02
Drugs
vinorelbinecapecitabinedocetaxeldexamethasone
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN66842537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN66842537.